Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management

Table 2 Table summarising treatments used

		Systemic treatments								Systemic CS		Topical treatments
		MTX	MMF	TCZ	ADA	AZA	ETN	ANK	CiC	IV	PO	CS	Vit D	Tac
Current treatment	No of patients	63	30	8	3	1	0	1	0	8	3	4	3	4
Current treatment	Median duration treatment months (IQR)	16.0 (9.3–24)	13.0 (6.0–25.5)	17.5 (15.8–24.0)	26.3	14	n/a	31	n/a	7.0 (3.5–10)	9.3
Previous treatment	No of patients	79	17	0	0	0	4	0	2	106	49	48	14	22
	Remission^a	34	5	n/a	n/a	n/a	0	n/a	0	103^a	45^a
	Inefficacy	8	6	n/a	n/a	n/a	3	n/a	2	0	3
	Intolerance	37	6	n/a	n/a	n/a	1	n/a	0	3	1
Never given	No of patients	7	102	141	146	148	145	148	147	35	97	97	132	123

MTX Methotrexate, MMF Mycophenolate mofetil, TCZ Tocilizumab, ADA Adalimumab, AZA Azathioprine, ETN Etanercept, ANK Anakinra, CiC Ciclosporin, IV Intravenous, PO Oral, CS Corticosteroid, Vit D Vitamin D analogue, Tac Tacrolimus, IQR Interquartile range
^aPatients treated with steroids were often given a standard treatment course whilst being established on a DMARD/biologic which is stopped after a standard interval according to local protocol rather than remission
The indication for commencement of a biological was not captured in this audit. A biological may have been commenced for refractory skin involvement or extra-cutaneous manifestations such as uveitis, CNS involvement or synovitis

ISSN: 1546-0096